Effect of bicalutamide 150 mg in non-metastatic prostate cancer with a median follow-up of three years: Analysis as a function of previous treatment and prognostic factors;Effet du bicalutamide 150 mg, à trois ans de suivi médian, dans le cancer de la prostate non métastatique

Progres en Urologie

Volumn 13, Issue 3, 2003, Pages 430-439

  Fourcade, Richard Olivier ^a   Richaud, Pierre ^b   Brune, Daniel ^c   Colombel, Paul ^d   Sarramon, Jean Pierre ^e   Fournier, Georges ^f   Colombeau, Pierre ^g  

^a Centre Hospitalier d'Auxerre   (France)

^b Institut Bergognie   (France)

^c CENTRE FRANÇOIS BACLESSE   (France)

^d Service d'Urologie   (France)

^e Service d'Urologie Andrologie   (France)

^f Service d'Urologie   (France)

^g LIMOGES UNIVERSITY HOSPITAL   (France)

Author keywords

Adjuvant therapy; Early endocrine; Prostate cancer

Indexed keywords

BICALUTAMIDE; PROSTATE SPECIFIC ANTIGEN; ANILIDE; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; GYNECOMASTIA; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MASTALGIA; MONOTHERAPY; OUTCOMES RESEARCH; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; STATISTICAL ANALYSIS; TREATMENT OUTCOME; ADULT; AGED; MALE; MIDDLE AGED; PROSTATE TUMOR; TIME;

ADULT; AGED; AGED, 80 AND OVER; ANILIDES; ANTINEOPLASTIC AGENTS; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 0642305880     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. BOLLA M., COLLETTE L., BLANK L., WARDE P., DUBOIS J.B., MIRIMANOFF R.O., STORME G., BERNIER J., KUTEN A., STERNBERG C., MATTELAER J., TORECILLA L.J., PFEFFER J.R., CUTAJAR C.L., ZURLO A., PIERART M. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study) : a phase III randomized trial. Lancet. 2002, 360, 103-108.
2. BYAR D.P., CORLE D.K. Hormone therapy for prostate cancer : results of the Veterans Administration Cooperative Urological Research Group Studies. NCI Monogr., 1988, 7, 165-170.
3. CHODAK G.W., KOLVENBAG G.J.C.M. Will the experience with tamoxifen in breast cancer help define the role of antiandrogens in prostate cancer? Pros. Cancer. Pros. Dis., 2001, 4, 72.
4. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer : an overview of the randomized trials. Early Breast Cancer Trialists' Collaborative Group. Lancet, 1998, 351, 1451-1467.
5. GRANFORS T., MODIG H., DAMBER J.E., TOMIC R. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without lymph node involvement : A prospective randomized study. J. Urol., 1998, 159, 2030.
6. IVERSEN P., TYRRELL C.J., KAISARY A.V., ANDERSON J.B., VAN POPPEL H., TAMMELA T.L., CHAMBERLAIN M., CARROLL K., MELEZINEK I. Bicalutamide (Casodex®) 150 mg monotherapy compared with castration in patients with non-metastatic locally advanced prostate cancer : 6,3 years follow-up. J. Urol., 2000, 164, 1579-1582.
7. IVERSEN P., WIRTH M., SEE W.A., McLeod D.G., MORRIS T., CARROLL K., on behalf of the Casodex Early Prostate Cancer Trialists Group. Is the efficacy of hormonal therapy affected by lymph nodule status? New data from the bicalutamide EPC program. Eur Urol Suppls, 2002, 1 (Abstr 528), 134.
8. KIRK D. Immediate versus deferred hormone treatment for prostate cancer : how safe is androgen deprivation? Br. J. Urol., 2000, 86 (Suppl 3), 220.
9. MCLEOD D.G., IVERSEN P. Gynecomastia in patients with prostate cancer : a review of treatment options. Urology, 2000, 56 : 713-720.
10. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer : Initial results of the Medical Research Council trial. Br. J. Urol., 1997, 79, 235-246.
11. MESSING E., MANOLA J., SAROSDY M., WILDING G., CRAWFORD E.D., TRUMP D. Immediate hormonal therapy in men with node-positive prostate cancer. New. Engl. J. Med., 1999, 341, 1781-1788.
12. PILEPICH M.V., CAPLAN R., BYHARDT R.W., LAWTON C.A., GALLAGHER M.J., MESIC J.B., HANKS G.E., COUGHLIN C.T., PORTER A., SHIPLEY W.U., GRIGNON D. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of radiation therapy oncology group protocol 85-31. J. Clin. Oncol., 1997, 15, 1013-1021.
13. POLLACK A., ZAGARS G.K., KAVADI V.S. Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer. Cancer, 1994, 74, 670-678.
14. SEE W.A., WIRTH M.P., McLEOD D.G., IVERSEN P., KLIMBERG I., GLEASON D., CHODAK G., MONTIE J., TYRRELL C., WALLACE D.M.A., DELAERE K.P.J., VAAGE S., TAMMELA T.L.J., LUKKARINEN O., PERSSON B-E., CARROLL K, KOLVENBAG G.J.C.M. on behalf of the Casodex early prostate cancer trialist group. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer : first analysis of the early prostate cancer program. J. Urol., 2002, 168, 429-435.
15. The Veterans Administration Co-operative Urological Research Group. Treatment and survival of patients with cancer of the prostate. Surg. Gynecol. Obstet., 1967, 124, 1011-1017.
16. WIRTH M., FROHMÜLLER H., MARZ F., BOLTEN M., THEIB M. Adjuvant antiandrogenic treatment after radical prostatectomy in stage C prostate cancer - preliminary results of a randomized controlled multicenter trial. J. Urol., 1997, 157 (Suppl), 335 (1308).